Bezpieczeństwo zastosowania etorykoksybu u pacjentów kardiologicznych przyjmujących bezpośrednie doustne antykoagulanty i nie tylko Opis przypadku
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2024
Słowa kluczowe:
etorykoksyb, niesteroidowe leki przeciwzapalne, ryzyko sercowo-naczyniowe, ryzyko żołądkowo-jelitowe
##plugins.themes.bootstrap3.article.main##
Abstrakt
Niesteroidowe leki przeciwzapalne są szeroko stosowaną grupą leków o działaniu przeciwbólowym, przeciwzapalnym i przeciwgorączkowym, jednak ich stosowanie wiąże się z ryzykiem działań niepożądanych, zwłaszcza ze strony układu sercowo-naczyniowego i przewodu pokarmowego. Etorykoksyb, selektywny inhibitor COX-2, charakteryzuje się skutecznością w łagodzeniu bólu oraz korzystnym profilem bezpieczeństwa, szczególnie w zakresie ryzyka krwawień z przewodu pokarmowego. Badania kliniczne potwierdziły, że etorykoksyb jest porównywalny pod względem ryzyka sercowo-naczyniowego z innymi niesteroidowymi lekami przeciwzapalnymi, a jednocześnie przewyższa je pod względem tolerancji i niższego ryzyka powikłań żołądkowo-jelitowych. Jego profil działania czyni go odpowiednim wyborem w leczeniu pacjentów wymagających przewlekłego stosowania niesteroidowych leków przeciwzapalnych, zwłaszcza tych z podwyższonym ryzykiem żołądkowo-jelitowym.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Skwarek, A., & Ozierański, K. (2024). Bezpieczeństwo zastosowania etorykoksybu u pacjentów kardiologicznych przyjmujących bezpośrednie doustne antykoagulanty i nie tylko . Medycyna Faktów , 17(4(65), 556-560. https://doi.org/10.24292/01.MF.0424.19
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Kim TJ, Kim ER, Hong SN et al. Effectiveness of acid suppressants and other mucoprotective agents in reducing the risk of occult gastrointestinal bleeding in nonsteroidal anti-inflammatory drug users. Sci Rep. 2019; 9(1): 11696.
2. Lanas A. A review of the gastrointestinal safety data – a gastroenterologist’s perspective. Rheumatology. 2010; 49(suppl. 2): ii3-10.
3. Medsafe New Zealand Medicines and Medical Devices Safety Authority. NSAIDs and cardiovascular risk.
4. Byrne RA, Rossello X, Coughlan JJ et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023; 44(38): 3720-826.
5. Graham DJ, Campen D, Hui R et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005; 365(9458): 475-81.
6. White WB, West CR, Borer JS et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol. 2007; 99(1): 91-8.
7. Caldwell B, Aldington S, Weatherall M et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006; 99(3): 132-40.
8. Kearney PM, Baigent C, Godwin J et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006; 332(7553): 1302-8.
9. Cannon CP, Curtis SP, FitzGerald GA et al.; MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006; 368(9549): 1771-81.
10. White WB, Faich G, Whelton A et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol. 2002; 89(4): 425-30.
11. Bombardier C, Laine L, Reicin A et al.; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000; 343(21): 1520-8, 2 p following 1528.
12. Kurth T, Glynn RJ, Walker AM et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation. 2003; 108(10): 1191-5.
13. Farkouh ME, Kirshner H, Harrington RA et al.; TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004; 364(9435): 675-84.
14. Chan FK, Lanas A, Scheiman J et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010; 376(9736): 173-9.
15. Cryer B, Li C, Simon LS et al. GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. Am J Gastroenterol. 2013; 108(3): 392-400.
16. Combe B, Swergold G, McLay J et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology (Oxford). 2009; 48(4): 425-32.
17. Laine L, Curtis SP, Cryer B et al.; MEDAL Steering Committee. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2007; 369(9560): 465-73.
18. European Medicines Agency. Question and answers on the review of etoricoxib – containing medicines. Doc. Ref. EMEA/329177/2008.
19. Song GG, Seo YH, Kim JH et al. Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis: A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal. Z Rheumatol. 2016; 75(5): 508-16.
2. Lanas A. A review of the gastrointestinal safety data – a gastroenterologist’s perspective. Rheumatology. 2010; 49(suppl. 2): ii3-10.
3. Medsafe New Zealand Medicines and Medical Devices Safety Authority. NSAIDs and cardiovascular risk.
4. Byrne RA, Rossello X, Coughlan JJ et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023; 44(38): 3720-826.
5. Graham DJ, Campen D, Hui R et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005; 365(9458): 475-81.
6. White WB, West CR, Borer JS et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol. 2007; 99(1): 91-8.
7. Caldwell B, Aldington S, Weatherall M et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006; 99(3): 132-40.
8. Kearney PM, Baigent C, Godwin J et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006; 332(7553): 1302-8.
9. Cannon CP, Curtis SP, FitzGerald GA et al.; MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006; 368(9549): 1771-81.
10. White WB, Faich G, Whelton A et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol. 2002; 89(4): 425-30.
11. Bombardier C, Laine L, Reicin A et al.; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000; 343(21): 1520-8, 2 p following 1528.
12. Kurth T, Glynn RJ, Walker AM et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation. 2003; 108(10): 1191-5.
13. Farkouh ME, Kirshner H, Harrington RA et al.; TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004; 364(9435): 675-84.
14. Chan FK, Lanas A, Scheiman J et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010; 376(9736): 173-9.
15. Cryer B, Li C, Simon LS et al. GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. Am J Gastroenterol. 2013; 108(3): 392-400.
16. Combe B, Swergold G, McLay J et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology (Oxford). 2009; 48(4): 425-32.
17. Laine L, Curtis SP, Cryer B et al.; MEDAL Steering Committee. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2007; 369(9560): 465-73.
18. European Medicines Agency. Question and answers on the review of etoricoxib – containing medicines. Doc. Ref. EMEA/329177/2008.
19. Song GG, Seo YH, Kim JH et al. Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis: A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal. Z Rheumatol. 2016; 75(5): 508-16.